One study showed that the GSK-3β inhibitor, AR-A014418 (ARA), inhibited BACE1-mediated APP cleavage into Aβ proteins in rodents [48], supporting the necessity of a GSK-3β-inhibiting drug for the treatment of AD. The gene discussed is GSK3B; the disease is Alzheimer disease.